Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited Fundamental Analysis
Advanced Enzyme Technologies Limited (ADVENZYMES.BO) shows moderate financial fundamentals with a PE ratio of 22.37, profit margin of 21.45%, and ROE of 10.57%. The company generates $7.1B in annual revenue with weak year-over-year growth of 2.15%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 57.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ADVENZYMES.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakADVENZYMES.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateADVENZYMES.BO shows balanced valuation metrics.
Growth Score
WeakADVENZYMES.BO faces weak or negative growth trends.
Financial Health Score
ExcellentADVENZYMES.BO maintains a strong and stable balance sheet.
Profitability Score
WeakADVENZYMES.BO struggles to sustain strong margins.
Key Financial Metrics
Is ADVENZYMES.BO Expensive or Cheap?
P/E Ratio
ADVENZYMES.BO trades at 22.37 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, ADVENZYMES.BO's PEG of 6.69 indicates potential overvaluation.
Price to Book
The market values Advanced Enzyme Technologies Limited at 2.29 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 13.25 times EBITDA. This signals the market has high growth expectations.
How Well Does ADVENZYMES.BO Make Money?
Net Profit Margin
For every $100 in sales, Advanced Enzyme Technologies Limited keeps $21.45 as profit after all expenses.
Operating Margin
Core operations generate 24.16 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.57 in profit for every $100 of shareholder equity.
ROA
Advanced Enzyme Technologies Limited generates $9.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Advanced Enzyme Technologies Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Advanced Enzyme Technologies Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
ADVENZYMES.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
22.37
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
6.69
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.29
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.80
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
8.75
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How ADVENZYMES.BO Stacks Against Its Sector Peers
| Metric | ADVENZYMES.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 22.37 | 27.18 | Better (Cheaper) |
| ROE | 10.57% | 860.00% | Weak |
| Net Margin | 21.45% | -121084.00% (disorted) | Strong |
| Debt/Equity | 0.02 | 0.41 | Strong (Low Leverage) |
| Current Ratio | 8.75 | 4.81 | Strong Liquidity |
| ROA | 9.00% | -7173.00% (disorted) | Weak |
ADVENZYMES.BO outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Advanced Enzyme Technologies Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
43.76%
Industry Style: Cyclical, Commodity, Value
High GrowthEPS CAGR
1.07%
Industry Style: Cyclical, Commodity, Value
GrowingFCF CAGR
5.47%
Industry Style: Cyclical, Commodity, Value
Growing